JEST
HRTX icon

JTC Employer Solutions Trustee’s Heron Therapeutics HRTX Stock Holding History

JTC Employer Solutions Trustee’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5K Hold
6,500
– – ﹤0.01% 289
2025
Q4 		$8K Hold
6,500
– – ﹤0.01% 286
2025
Q3 		$8K Hold
6,500
– – ﹤0.01% 286
2025
Q2 		$13K Hold
6,500
– – ﹤0.01% 272
2025
Q1 		$14K Hold
6,500
– – ﹤0.01% 282
2024
Q4 		$10K Hold
6,500
– – ﹤0.01% 289
2024
Q3 		$13K Hold
6,500
– – ﹤0.01% 295
2024
Q2 		$23K Hold
6,500
– – ﹤0.01% 277
2024
Q1 		$18K Hold
6,500
– – ﹤0.01% 299
2023
Q4 		$11K Hold
6,500
– – ﹤0.01% 308
2023
Q3 		$7K Hold
6,500
– – ﹤0.01% 327
2023
Q2 		$8K Hold
6,500
– – ﹤0.01% 331
2023
Q1 		$10K Hold
6,500
– – ﹤0.01% 332
2022
Q4 		$16K Hold
6,500
– – ﹤0.01% 328
2022
Q3 		$27K Hold
6,500
– – ﹤0.01% 251
2022
Q2 		$18K Hold
6,500
– – ﹤0.01% 243
2022
Q1 		$37K Hold
6,500
– – ﹤0.01% 226
2021
Q4 		$59K Hold
6,500
– – 0.01% 203
2021
Q3 		$70K Hold
6,500
– – 0.01% 191
2021
Q2 		$101K Buy
+6,500
New +$103K 0.01% 162

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

JTC Employer Solutions Trustee's HRTX Position: Q1 2026 in Review

JTC Employer Solutions Trustee held its Heron Therapeutics (HRTX) position steady in Q1 2026 at 6,500 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #289.

JTC Employer Solutions Trustee first reported a position in HRTX in Q2 2021 and has held it in 20 quarters since. The position peaked at $101K in Q2 2021. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • JTC Employer Solutions Trustee held 6,500 shares of Heron Therapeutics worth $5K as of Q1 2026.
  • JTC Employer Solutions Trustee left its Heron Therapeutics share count unchanged in Q1 2026.
  • Heron Therapeutics made up ﹤0.01% of JTC Employer Solutions Trustee's portfolio in Q1 2026, its #289 holding.
  • JTC Employer Solutions Trustee first reported a position in Heron Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • JTC Employer Solutions Trustee's Heron Therapeutics position peaked at $101K in Q2 2021.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on JTC Employer Solutions Trustee's 13F filing for Q1 2026, filed 19 May 2026.